Causes of Lytic Bone Lesions
Lytic bone lesions arise from four primary categories: malignant neoplasms (metastatic disease and multiple myeloma being most common), primary bone tumors, infections (particularly tuberculosis), and metabolic/endocrine disorders.
Malignant Causes (Most Common)
Metastatic Disease
Metastatic bone disease represents the most frequent cause of lytic lesions in adults, particularly from:
- Breast cancer (70% develop bone metastases)
- Lung cancer (40%)
- Renal cell carcinoma (40%)
- Thyroid cancer
- Melanoma 1
These cancers preferentially affect the axial skeleton and cause skeletal-related events including pathological fractures, requiring radiation or surgery, and spinal cord compression 1.
Multiple Myeloma
Multiple myeloma causes lytic lesions in 95% of patients and presents with extensive bone destruction that typically does not heal even after successful treatment 1. The diagnosis requires:
- Serum M-protein ≥3 g/dL and/or
- Bone marrow plasma cells ≥10%
- Plus skeletal involvement (lytic lesions), anemia, hypercalcemia, or renal insufficiency 2
Critical diagnostic pitfall: A single asymptomatic lytic lesion may represent a benign bone cyst or angioma rather than myeloma—CT or MRI is essential for differentiation 2.
Primary Bone Malignancies
Primary bone sarcomas (osteosarcoma, chondrosarcoma, Ewing sarcoma) are rare (1 per 100,000 persons/year) but must be considered, particularly in younger patients 3, 4.
Infectious Causes
Tuberculous Osteomyelitis
Tuberculosis can produce isolated lytic bone lesions that closely mimic malignancy, including bone cysts, osteoblastoma, osteosarcoma, and metastatic disease radiologically 5, 6. This occurs even in immunocompetent patients without pulmonary symptoms or TB risk factors 6.
Key recommendation: Include mycobacterial cultures when analyzing biopsies of lytic bone lesions, as TB osteomyelitis is easily missed 6.
Metabolic/Endocrine Causes
Brown Tumors (Hyperparathyroidism)
Brown tumors are benign focal lytic lesions caused by rapid osteoclastic activity from primary hyperparathyroidism, typically due to parathyroid adenoma 7. These resolve after adenoma removal.
Diagnostic clue: Mild to moderate stable hypercalcemia with lytic lesions should prompt serum parathyroid hormone measurement, especially when lytic lesions are absent elsewhere 2.
Diagnostic Approach Algorithm
Initial Evaluation
- Full skeletal radiographic survey remains the standard for detecting lytic lesions 8, 9
- Laboratory workup must include:
Advanced Imaging Selection
- MRI: Most sensitive for early marrow infiltration before osseous response; detects lesions missed by bone scan 10
- CT: Superior for anatomically complex sites (skull, spine, pelvis) and characterizing lesion margins 10, 3
- Bone scintigraphy: Highly sensitive for osteoblastic/mixed lesions but relatively insensitive for purely lytic lesions from renal cancer, thyroid cancer, and multiple myeloma (sensitivity 62-100%, lowest in lytic disease) 10
- FDG-PET: Detects purely osteolytic lesions and marrow infiltration by assessing metabolic activity rather than bony response 10
Tissue Diagnosis
Histological confirmation via CT-guided biopsy is essential when:
- Bone-only disease with few or equivocal lesions
- Negative myeloma screening despite suspicious imaging
- Need to assess predictive biomarkers for treatment planning 11
Always request mycobacterial cultures alongside routine histopathology 6.
Common Diagnostic Pitfalls
Assuming all lytic lesions in elderly patients are malignant: Consider coincidental conditions like osteoporosis, benign cysts, or hyperparathyroidism 2
Relying solely on bone scan: This modality has poor sensitivity for purely lytic lesions and can miss myeloma, renal cell carcinoma, and thyroid metastases 10
Missing tuberculosis: TB osteomyelitis mimics malignancy radiologically and occurs without pulmonary symptoms—always culture for mycobacteria 5, 6
Overlooking lymphoma: Diffuse large B-cell lymphoma can present with multiple lytic lesions, hypercalcemia, and negative myeloma screening, mimicking myeloma 12